Transmitted drug-resistant HIV type 1 remains prevalent and impacts virologic outcomes despite genotype-guided antiretroviral therapy

AIDS Research and Human Retroviruses

Volumn 28, Issue 3, 2012, Pages 259-264

  Taniguchi, Toshibumi ^a   Nurutdinova, Diana ^b   Grubb, Jessica R ^a   Önen, Nur F ^a   Shacham, Enbal ^c   Donovan, Michael ^a   Overton, Edgar Turner ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c WASHINGTON UNIVERSITY IN ST LOUIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ADULT; ARTICLE; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TREATMENT FAILURE; VIRUS MUTATION;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; PREVALENCE; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 84858122902     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0022     Document Type: Article

References (24)

1. Palella FJ, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al.: Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43(1):27-34. (Pubitemid 44306484)
2. Holmberg SD, Hamburger ME, Moorman AC, Wood KC, and Palella FJ: Factors associated with maintenance of long-term plasma human immunodeficiency virus RNA suppression. Clin Infect Dis 2003;37(5):702-707. (Pubitemid 37100813)
3. Robbins GK, Johnson KL, Chang Y, Jackson KE, Sax PE, Meigs JB, et al.: Predicting virologic failure in an HIV clinic. Clin Infect Dis 2010;50(5):779-786.
4. Johnson JA, Li J, Wei X, Lipscomb J, Irlbeck D, Craig C, et al.: Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med 2008; 5(7):e158.
5. Metzner KJ, Giulieri SG, Knoepfel SA, Rauch P, Burgisser P, Yerly S, et al.: Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and-adherent patients. Clin Infect Dis 2009;48(2):239-247.
6. Pillay D, Bhaskaran K, Jurriaans S, Prins M, Masquelier B, Dabis F, et al.: The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS 2006;20(1):21-28. (Pubitemid 41818110)
7. Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, Poole L, et al.: Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. PLoS ONE 2010;5(12):e15510.
8. Rahim S, Fredrick LM, da Silva BA, Bernstein B, and King MS: Geographic and temporal trends of transmitted HIV-1 drug resistance among antiretroviral-naïve subjects screening for two clinical trials in North America and Western Europe. HIV Clin Trials 2009;10(2):94-103.
9. Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, Bodnar UR, et al.: Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 2010;24(8):1203-1212.
10. von Wyl V, Yerly S, Burgisser P, Klimkait T, Battegay M, Ber-nasconi E, et al.: Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clin Infect Dis 2009;48(7):979-987.
11. Costagliola D, Descamps D, Assoumou L, Morand-Joubert L, Marcelin A, Brodard V, et al.: Prevalence of HIV-1 drug resistance in treated patients: A French nationwide study. J Acquir Immune Defic Syndr 2007;46(1):12-18. (Pubitemid 47507429)
12. Vercauteren J, Wensing AMJ, van de Vijver DAMC, Albert J, Balotta C, Hamouda O, et al.: Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009;200(10):1503-1508.
13. Bracciale L, Colafigli M, Zazzi M, Corsi P, Meraviglia P, Micheli V, et al.: Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: Evolution over 12 years and predictors. J Antimicrob Chemother 2009;64(3):607-615.
14. Sax PE, Islam R, Walensky RP, Losina E, Weinstein MC, Goldie SJ, et al.: Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005;41(9):1316-1323. (Pubitemid 41532676)
15. Weinstein MC, Goldie SJ, Losina E, Cohen CJ, Baxter JD, Zhang H, et al.: Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med 2001;134(6):440-450. (Pubitemid 32225945)
16. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. May 4, 2006; 1-112. Accessed 2011 Jan 18. Available from http://aidsinfo.nih.gov/ContentFiles/Adul- tandAdolescentGL05042006050.pdf
17. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al.: Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 2009;4(3):e4724.
18. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, et al.: Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358(20):2095-2106. (Pubitemid 351679596)
19. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Bud-hathoki C, et al.: Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV type-1: A randomized trial. Ann Intern Med 2011;154(7):445-456.
20. Puls RL, Srasuebkul P, Petoumenos K, Boesecke C, Dun-combe C, Belloso WH, et al.: Efavirenz versus boosted ata-zanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: Week 48 data from the Altair Study. Clin Infect Dis 2010;51(7):855-864.
21. Kimberly S, Tiernney C, Daar E, Mollan K, Budhathoki C, Sax P, et al.: Association of Race/Ethnicity and Sex on Outcomes in ACTG Study A5202. Abstract 536. Presented at the 18th Conference on Retroviruses and Opportunistic Infections. February 27-March 2, 2011, Boston.
22. Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, Baxter JD, et al.: Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 2009;199(5):693-701.
23. Kim D, Wheeler W, Ziebell R, et al.: Prevalence of transmitted antiretroviral drug resistance among newly-diagnosed HIV-1-infected persons, US, 2007. Abstract 580. Presented at the 17th Conference on Retroviruses and Opportunistic Infections. February 16-19, 2010, San Francisco.
24. Mugavero MJ, May M, Harris R, Saag MS, Costagliola D, Egger M, et al.: Does short-term virologic failure translate to clinical events in antiretroviral-näive patients initiating an-tiretroviral therapy in clinical practice? AIDS 2008;22(18): 2481-2492.